MergerJun 24, 2026, 06:07 AM
Liminatus Pharma to Acquire InnocsAI for 1.6B Shares
AI Summary
Liminatus Pharma, a pre-clinical stage life sciences company, entered into a Merger Agreement to acquire InnocsAI LLC, gaining a portfolio of oncology-focused biologic and cellular therapy programs. The consideration for InnocsAI includes 1.6 billion shares of common stock at $0.20 per share and contingent value rights. Concurrently, the company completed a warrant inducement with Armistice Capital, receiving $1.86 million from the exercise of existing warrants at a reduced price of $0.18 per share, and issued new inducement warrants for up to 20.688 million shares.
Key Highlights
- Liminatus Pharma to acquire InnocsAI LLC via a merger agreement.
- Merger consideration includes 1,600,000,000 shares of common stock at $0.20/share.
- Acquisition adds oncology-focused biologic and cellular therapy programs.
- Entered Inducement Letter Agreement with Armistice Capital for warrant exercise.
- Received $1,861,920 from existing warrant exercise at $0.18 per share.
- Issued new Inducement Warrants for up to 20,688,000 shares at $0.18 per share.
- Common stock outstanding: 50,607,633 shares, potentially up to 71,295,633 after offering.
- Common stock trades on Nasdaq under 'LIMN', last reported price $0.11/share.
Price Impact
More from LIMN